Molecular Partners AG — FY2022 Form 20-F
Reporting period: Year ended December 31, 2022; this is an annual report, not a standalone Q4 filing. The company is a Swiss clinical-stage biopharmaceutical business focused on its DARPin platform, principally in oncology and virology. Financial statements are prepared under IFRS in Swiss francs (CHF).
Financial results and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Collaboration revenue and other income | CHF 189.6 million | CHF 9.8 million |
| Research and development expense | CHF 50.7 million | CHF 55.7 million |
| Selling, general and administrative expense | CHF 22.2 million | CHF 17.5 million |
| Operating result | CHF 116.6 million | Loss of CHF 63.4 million |
| Net result attributable to shareholders | Profit of CHF 117.9 million | Loss of CHF 63.8 million |
| Operating cash flow | CHF 118.6 million | Use of CHF 91.0 million |
| Cash, cash equivalents and short-term deposits | CHF 249.1 million | CHF 132.8 million |
The sharp improvement in revenue and earnings primarily reflects Novartis’s January 2022 exercise of its ensovibep option, which triggered a CHF 150 million payment. Revenue also included recognition of a CHF 7 million Swiss Federal Office of Public Health reservation fee and collaboration income. The company has no approved products and has never generated product-sale revenue; consequently, a conventional product gross margin is not meaningful. Results are highly dependent on irregular collaboration payments.
Total assets were CHF 262.3 million and shareholders’ equity CHF 235.2 million at year-end. The company reported no short- or long-term debt; lease liabilities totaled CHF 4.9 million. Management said available cash and deposits, together with anticipated collaboration funding, were expected to cover operating expenses and capital spending into 2026, subject to assumptions that may prove incorrect. A $100 million ATM share-sale facility was established in July 2022; no sales had been made under it as of March 8, 2023.
Material changes and business developments
- Revenue rose from CHF 9.3 million in 2021 to CHF 189.6 million in 2022, chiefly due to the one-time ensovibep option exercise. Net income therefore does not indicate recurring profitability.
- Operating expenses were broadly stable at CHF 73.0 million, down slightly from CHF 73.2 million. R&D expense fell, while SG&A rose 28%, including U.S. public-company, insurance and personnel costs.
- MP0310 global rights returned to Molecular Partners after Amgen’s strategic review in April 2022.
- Novartis’s radioligand collaboration generated a $20 million upfront payment (CHF 18.6 million); the company may receive up to $560 million in future milestones and tiered royalties if development and sales milestones are achieved.
- Novartis exercised its ensovibep option and received worldwide development and commercialization rights. The company is entitled to a 22% royalty on future commercial sales, with royalties waived in lower-income countries. Ensovibep development was halted in 2022 after it lacked neutralization activity against Omicron subvariants; Novartis’s EUA withdrawal request became effective January 25, 2023.
- MP0317 Phase 1 interim data presented in November 2022 showed tumor-localized CD40 activation and, to date, no dose-limiting CD40-related systemic toxicity or signs of inflammatory cytokine release. The dose-escalation trial was ongoing at filing.
- MP0533 entered Phase 1 in January 2023. Management anticipated preliminary clinical results by Q4 2023; this is a forward-looking expectation, not a reported outcome.
Outlook, risks and unusual items
Management expects continued investment in R&D and operating expenses, and warns that further losses are likely despite the 2022 profit. The company’s funding runway depends on clinical progress, costs, partner activity and access to capital. Its pipeline remains preclinical or in clinical development, with uncertain trial results, regulatory approval and commercialization prospects.
- Clinical and regulatory risk: Trials may be delayed, fail or reveal safety concerns; early or interim findings may change as data mature. Manufacturing or supply issues, including bioburden or particles at contract manufacturers, could disrupt development.
- Partner dependence: Licensees control important development and commercialization activities, and may deprioritize programs. The ensovibep halt and MP0310 rights return illustrate this exposure.
- Intellectual property: The main University of Zurich DARPin base patents expired in September 2021, except for one U.S. patent then expected to expire in August 2023. The company states that competitors may use technology covered by expired patents.
- Legal contingency: A putative U.S. securities class action filed in July 2022 alleges misrepresentations or omissions concerning ensovibep and MP0310. The case was at an early stage; damages sought were unspecified, and the company disputes the claims.
- Other exposures: Foreign-exchange movements, reliance on third-party manufacturers and CROs, data security and privacy, competition, and changing drug-pricing and reimbursement rules could affect results. The company disclosed no currency hedging transactions in 2022.
- Tax and shareholder matters: The filing states that the company believes it was a passive foreign investment company (PFIC) for U.S. tax purposes in 2022. It does not anticipate dividends in the foreseeable future.
Key facts for investors to verify
- How much of 2022’s CHF 189.6 million revenue and CHF 117.9 million profit was non-recurring, and what recurring collaboration or royalty revenue remains?
- Whether the stated runway into 2026 remains valid after ensovibep was halted and what assumptions it uses for spending, partnerships and clinical plans.
- Current clinical status, safety findings and timelines for MP0317 and MP0533, including whether anticipated milestones were achieved.
- Current status and potential value of the Novartis radioligand collaboration, including milestone conditions and partner development progress.
- The securities lawsuit’s subsequent status, potential exposure and any material developments after the filing.
- The share-count disclosures: the cover reports 36,044,706 shares outstanding at year-end, while the financial statements distinguish 3.5 million treasury shares and note 252,058 shares registered in February 2023. Reconcile issued, outstanding, treasury and ADS-linked shares before assessing dilution.